Please use this identifier to cite or link to this item:
Title: Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Austin Authors: Kubota, E;Dean, Rachael G;Hubner, R A;Balding, Leanne C;Johnston, Colin I;Burrell, Louise M 
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Studley Road, Heidelberg 3084, Victoria, Australia
Issue Date: 1-Dec-2001
Publication information: Current Hypertension Reports; 3 Suppl 2(): S31-3
Abstract: In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme is responsible for the conversion of angiotensin I to angiotensin II, while neutral endopeptidase is one of the pathways involved in the degradation of the natriuretic peptides. The vasopeptidase inhibitors, which simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme, appear to offer distinct therapeutic advantages in treating hypertension, heart failure, and endothelial dysfunction.
Gov't Doc #: 11716804
Journal: Current hypertension reports
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.pharmacology
Cardiotonic Agents.pharmacology
Endothelium, Vascular.drug effects
Heart.drug effects
Heart Failure.drug therapy
Hypertension.drug therapy
Kidney.drug effects
Kidney Failure, Chronic.drug therapy.etiology
Neprilysin.antagonists & inhibitors
Renin-Angiotensin System.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 3, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.